Literature DB >> 19385975

Aberrant DNA methylation profile of hepatocellular carcinoma and surgically resected margin.

Cheng Lou1, Zhi Du, Bin Yang, YingTang Gao, YiJun Wang, ShuChang Fang.   

Abstract

Field cancerization currently described the theory of tumorigenesis and, until now, has been described in almost all organ systems except in liver. For this reason, we explore the presence of field cancerization in liver and its underlying clinical implication in hepatocellular carcinoma (HCC). In our study, methylation profile of HCC and surgically resected margin (SRM) were established by methylation-specific PCR. Liver cirrhosis (LC), chronic hepatitis and normal liver were treated in the same way as the background control. The correlation analysis among the methylation profile of HCC, SRM and clinicopathological data of HCC patients was made respectively. Our results showed that methylation abnormities related to HCC, but not background disease existed in histologically negative SRM. Monoclonal and polyclonal models may coexist in field cancerization in liver. Patients with RIZ1 methylation in SRM had a shorter disease free survival. The local recurrence trend of early and later recurrence in HCC is potentially related to a second field tumor. From these results, we can suggest that field cancerization exists in liver. The study of field cancerization in liver plays an important role in hepatocarcinogenesis. Second field tumor derived form field cancerization may have important implications in HCC prognosis assessment that is worthy of further study.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19385975     DOI: 10.1111/j.1349-7006.2009.01138.x

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  22 in total

Review 1.  Role of epigenetic aberrations in the development and progression of human hepatocellular carcinoma.

Authors:  Igor P Pogribny; Ivan Rusyn
Journal:  Cancer Lett       Date:  2012-02-02       Impact factor: 8.679

2.  Role of RASSF1A promoter methylation in the pathogenesis of hepatocellular carcinoma: a meta-analysis of 21 cohort studies.

Authors:  Yong-Shuang Li; Qiang Xie; Da-Ye Yang; Yuan Zheng
Journal:  Mol Biol Rep       Date:  2014-02-25       Impact factor: 2.316

3.  Comparative analysis of promoter methylation and gene expression endpoints between tumorous and non-tumorous tissues from HCV-positive patients with hepatocellular carcinoma.

Authors:  Eric J Formeister; Masato Tsuchiya; Hideki Fujii; Svitlana Shpyleva; Igor P Pogribny; Ivan Rusyn
Journal:  Mutat Res       Date:  2010-08-22       Impact factor: 2.433

4.  New strategies in hepatocellular carcinoma: genomic prognostic markers.

Authors:  Augusto Villanueva; Yujin Hoshida; Sara Toffanin; Anja Lachenmayer; Clara Alsinet; Radoslav Savic; Helena Cornella; Josep M Llovet
Journal:  Clin Cancer Res       Date:  2010-08-16       Impact factor: 12.531

5.  Methylation of Dickkopf-3 as a prognostic factor in cirrhosis-related hepatocellular carcinoma.

Authors:  Bin Yang; Zhi Du; Ying-Tang Gao; Cheng Lou; Shi-Guang Zhang; Tong Bai; Yi-Jun Wang; Wen-Qin Song
Journal:  World J Gastroenterol       Date:  2010-02-14       Impact factor: 5.742

6.  Hypermethylation of ACP1, BMP4, and TSPYL5 in Hepatocellular Carcinoma and Their Potential Clinical Significance.

Authors:  Xueping Qiu; Bo Hu; Yifang Huang; Yunte Deng; Xuebin Wang; Fang Zheng
Journal:  Dig Dis Sci       Date:  2015-09-19       Impact factor: 3.199

7.  Gene expression in nontumoral liver tissue and recurrence-free survival in hepatitis C virus-positive hepatocellular carcinoma.

Authors:  Masato Tsuchiya; Joel S Parker; Hiroshi Kono; Masanori Matsuda; Hideki Fujii; Ivan Rusyn
Journal:  Mol Cancer       Date:  2010-04-09       Impact factor: 27.401

8.  Aberrant methylation of SPARC in human hepatocellular carcinoma and its clinical implication.

Authors:  Ye Zhang; Bin Yang; Zhi Du; Tong Bai; Ying-Tang Gao; Yi-Jun Wang; Cheng Lou; Feng-Mei Wang; Yu Bai
Journal:  World J Gastroenterol       Date:  2012-05-07       Impact factor: 5.742

Review 9.  Translational medicine in hepatocellular carcinoma.

Authors:  Qiang Gao; Yinghong Shi; Xiaoying Wang; Jian Zhou; Shuangjian Qiu; Jia Fan
Journal:  Front Med       Date:  2012-05-09       Impact factor: 4.592

10.  Prognostic Model for the Risk Stratification of Early and Late Recurrence in Hepatitis B Virus-Related Small Hepatocellular Carcinoma Patients with Global Histone Modifications.

Authors:  Jin-Ling Duan; Run-Cong Nie; Zhi-Cheng Xiang; Jie-Wei Chen; Min-Hua Deng; Hu Liang; Feng-Wei Wang; Rong-Zhen Luo; Dan Xie; Mu-Yan Cai
Journal:  J Hepatocell Carcinoma       Date:  2021-05-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.